Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Operating Leases (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Operating Leases for 5 consecutive years, with $4.2 million as the latest value for Q2 2025.

  • For Q2 2025, Operating Leases changed 0.0% year-over-year to $4.2 million; the TTM value through Jun 2025 reached $4.2 million, changed 0.0%, while the annual FY2024 figure was $2.3 million, 60.25% down from the prior year.
  • Operating Leases hit $4.2 million in Q2 2025 for Kezar Life Sciences, up from $1.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.9 million in Q4 2022 and bottomed at $1.4 million in Q1 2025.
  • Average Operating Leases over 5 years is $4.4 million, with a median of $4.0 million recorded in 2021.
  • Year-over-year, Operating Leases skyrocketed 201.31% in 2023 and then plummeted 73.02% in 2025.
  • Kezar Life Sciences' Operating Leases stood at $3.2 million in 2021, then soared by 175.05% to $8.9 million in 2022, then plummeted by 33.99% to $5.9 million in 2023, then plummeted by 60.25% to $2.3 million in 2024, then soared by 78.5% to $4.2 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $4.2 million, $1.4 million, and $2.3 million for Q2 2025, Q1 2025, and Q4 2024 respectively.